Valion Bio
VBIO
4 hedge funds and large institutions have $187K invested in Valion Bio in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
345,431% more capital invested
Capital invested by funds: $54 → $187K (+$187K)
100% more funds holding
Funds holding: 2 → 4 (+2)
5.12% more ownership
Funds ownership: 0% → 5.12% (+5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$169K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$24.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$17 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MG
1
Marex Group
London,
| $163K | +$169K | +39,283 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $23.5K | +$24.3K | +5,653 | New |
|
|
SS
3
SBI Securities
Tokyo,
Japan
| $66 | – | – | – |
|
|
4
Bank of America
Charlotte,
North Carolina
| $37 | +$17 | +4 | +80% |
|
VBIO Hedge Fund Activity: Q2 2025 in Review
4 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2025, worth a combined $187K — up 345,431% from $54 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $169K.
- 4 institutional investors held Valion Bio (VBIO) as of Q2 2025, up from 2 in Q1 2025.
- Funds reported $187K of Valion Bio stock for Q2 2025, up 345,431% quarter-over-quarter.
- 2 funds opened new Valion Bio positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest Valion Bio buyer in Q2 2025 was Marex Group, an estimated $169K added.
Based on aggregated 13F filings for Q2 2025.